MedPage Today roundup: FDA approves ropeginterferon alfa-2b for essential thrombocythemia — first new therapy for this myeloproliferative neoplasm since 1997

The FDA approved ropeginterferon alfa-2b (Besremi) for adults with essential thrombocythemia, marking the first new therapy for this chronic myeloproliferative neoplasm since anagrelide's approval in 1997. The roundup also highlights emerging data on AI-assisted mammography screening and a positive phase III trial result in multiple myeloma. Although Besremi was previously approved for polycythemia vera, the new indication fills a nearly three-decade treatment gap for ET patients.